The novel new vaccine, which involves injecting weakened malarial-inducing parasites into patients in order to elicit a degree of immunity, has been having successful results. The U.S. biotech company, Sanaria, hopes for continued success in order to alleviate the impact of the widespread disease.

Read the story.